1. Home
  2. EMF vs BWAY Comparison

EMF vs BWAY Comparison

Compare EMF & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Emerging Markets Fund

EMF

Templeton Emerging Markets Fund

HOLD

Current Price

$16.39

Market Cap

254.5M

Sector

Finance

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$18.07

Market Cap

337.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EMF
BWAY
Founded
1987
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Finance/Investors Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
254.5M
337.9M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
EMF
BWAY
Price
$16.39
$18.07
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$23.50
AVG Volume (30 Days)
29.3K
62.4K
Earning Date
01-01-0001
11-11-2025
Dividend Yield
6.16%
N/A
EPS Growth
N/A
213.09
EPS
N/A
0.13
Revenue
N/A
$49,094,000.00
Revenue This Year
N/A
$330.76
Revenue Next Year
N/A
$22.24
P/E Ratio
N/A
$53.33
Revenue Growth
N/A
27.08
52 Week Low
$10.58
$7.84
52 Week High
$12.67
$18.18

Technical Indicators

Market Signals
Indicator
EMF
BWAY
Relative Strength Index (RSI) 36.59 60.77
Support Level $16.20 $15.97
Resistance Level $16.62 $17.38
Average True Range (ATR) 0.22 0.64
MACD -0.11 -0.02
Stochastic Oscillator 11.39 92.52

Price Performance

Historical Comparison
EMF
BWAY

About EMF Templeton Emerging Markets Fund

Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: